Post-Kenvue JNJ trades at 22x earnings with a looming Stelara patent cliff worth $4-5 billion in annual revenue. The defensive premium is priced for a company that no longer exists.
The consensus on Johnson & Johnson is straightforward: it is the ultimate defensive stock. Blue-chip healthcare, 62 consecutive years of dividend increases, a AAA credit rating shared with only one other company on the planet. Portfolio managers buy it when they want to sleep at night.
The problem is that the JNJ trading at 22x earnings today is a fundamentally different company than the one that earned that reputation. The Kenvue spinoff in 2023 stripped out the consumer health division — the Band-Aids, the Tylenol, the Listerine — and left behind a concentrated pharmaceutical and medtech business with a looming patent cliff that the multiple completely ignores.
The defensive premium is priced for a conglomerate that no longer exists. The underlying business demands a risk premium instead.
Revenue dropped from $85.2 billion in 2023 to $55.6 billion in 2024 — a 35% decline that was entirely structural, not cyclical. The consumer health segment that Kenvue took with it generated stable, recession-proof cash flows with minimal R&D risk. What remains is a pharmaceutical division generating roughly 55% of revenue and a medtech division at 45%.
The pharma side is dominated by a single franchise: Stelara, which generated approximately $10.4 billion in peak revenue. Biosimilar competition arrived in early 2025 in Europe and is coming to the US. Consensus estimates project Stelara revenue declining 40-50% over the next three years. That is not a rounding error — it is a structural revenue hole worth $4-5 billion annually.
TickerXray Report
Get the complete Johnson & Johnson report with all 12 quantitative models, AI-generated investment thesis, and real-time data.
Pharma investors know patent cliffs happen. The standard response is to point at the pipeline. JNJ's pipeline is, by most accounts, solid — Tremfya in immunology, Tecvayli in multiple myeloma, and a growing oncology portfolio anchored by Darzalex. The Street is modelling these assets to fill the Stelara hole by 2028.
The maths requires optimistic assumptions. Tremfya would need to reach $8-10 billion in annual sales — achievable but not guaranteed given competition from AbbVie's Skyrizi and Rinvoq. Tecvayli is in a crowded bispecific antibody space. And Darzalex, while dominant in myeloma, is already at $10 billion in revenue with limited upside surprise left.
Across three complete pharma patent cycles — Pfizer's Lipitor cliff in 2012, Merck's Singulair loss the same year, AbbVie's Humira erosion starting 2023 — the pattern is remarkably consistent: consensus underestimates the revenue decline by 15-25% and overestimates pipeline replacement timelines by 12-18 months.
There is no reason to believe JNJ will be the exception.
At $158 per share and a trailing P/E of 22.2x, JNJ trades at a premium to its large-cap pharma peers. Merck sits at 13.8x. AbbVie at 15.3x. Pfizer, admittedly dealing with its own post-COVID hangover, at 24.7x but on depressed earnings. The forward P/E of 13.6x looks more reasonable — until you consider what that forward estimate assumes.
The Street's consensus for 2027 earnings per share is roughly $11.50, which requires Stelara erosion to be fully offset by pipeline ramps and medtech growth of 6-7% annually. If Stelara declines 10% faster than modelled, or if Tremfya's launch trajectory falls short by even 15%, that EPS estimate drops to $10.00-10.50. At that level, the forward P/E jumps back to 15-16x — still a premium to peers, but now without the growth to justify it.
Then there is the talc litigation. JNJ's third attempt at a bankruptcy manoeuvre to resolve the claims failed in court, and the company now faces an estimated $8-10 billion in potential settlement costs. Management has signalled willingness to settle, but the final number remains uncertain. The market has largely shrugged this off — another sign that the defensive premium is shielding the stock from proper risk pricing.
Johnson & Johnson at 22x trailing earnings is a stock priced for the safety of a diversified healthcare conglomerate. The actual business is a concentrated pharma-and-medtech operation facing a multi-billion-dollar patent cliff, uncertain pipeline timelines, and unresolved litigation. The 3.6% dividend yield provides some cushion, but it is not enough to compensate for 15-20% downside if Stelara erosion accelerates.
We would be buyers below $130, where the valuation starts to reflect the actual risk profile. At current levels, the market is paying for certainty that does not exist.
Full forensic analysis of Johnson & Johnson
+ 6 more models included
150,000+ stocks covered
Global coverage across 60+ exchanges. Every report includes all 12 quantitative models and AI analysis.
View plansEvery report runs 12 quantitative models and generates an AI investment thesis. From Piotroski scores to manipulation detection -- get the full picture in seconds.
12 forensic models
Piotroski, Altman, Beneish, DuPont & more
AI investment thesis
Synthesized outlook on every stock
Manipulation detection
Spot red flags before they hit the news
150,000+ tickers
Global coverage across 60+ exchanges
Expected return
Forward return projections for every stock
Real-time data
Live prices, insider trades, news sentiment
Free accounts get 1 report per month. Pro gets unlimited.
The pharma franchise is doing the work, but the consolidated balance sheet, the talc litigation overhang, and the medical device segment exposure to FDA leadership turnover deserve more weight in the equity case.
Pfizer trades at 9x forward earnings, J&J at 20x. The valuation gap implies one is a value trap. The data says it's the other way around.
Revenue passed $94 billion, operating income hit $25.6 billion, and the MedTech segment is quietly compounding at double-digit rates while the market is still processing the Kenvue separation.